Albemarle (ALB) Rises Amid Market Downturn: Key Facts

Albemarle (ALB) rose 1.76% to $77.07, outperforming the S&P 500's loss of 0.01%. The company's stock has gained 27.51% over the past month, exceeding the Basic Materials sector's gain of 1.67% and the S&P 500's gain of 5.37%. Albemarle's earnings report on July 30, 2025, is expected to show a year-over-year decline of 2175% in earnings per share and a 13.67% decline in revenue. The Zacks Rank system has a history of outperforming with #1 stocks returning an average annual gain of +25% since 1988.

Albemarle Corporation (ALB) ended the recent trading session at $77.07, demonstrating a +1.76% change from the preceding day's closing price. This performance outpaced the S&P 500's daily loss of 0.01%. Elsewhere, the Dow lost 0.32%, while the tech-heavy Nasdaq added 0.05% [1].

Shares of the specialty chemicals company have appreciated by 27.51% over the past month, outperforming the Basic Materials sector's gain of 1.67% and the S&P 500's gain of 5.37% [1]. Albemarle's stock has considerably underperformed the S&P 500 Index's 12.1% gains over the past 52 weeks, with shares down 27.5% during this period [2].

The investment community will be closely monitoring Albemarle's forthcoming earnings report. The company is scheduled to release its earnings on July 30, 2025. Analysts expect Albemarle to report a loss of -$0.83 per share, which would represent a year-over-year decline of 2175%. Meanwhile, the consensus estimate calls for revenue of $1.23 billion, down 13.67% from the prior-year quarter [1].

Looking at the full year, Zacks Consensus Estimates suggest analysts are expecting earnings of -$2.02 per share and revenue of $4.86 billion. These totals would mark changes of +13.68% and -9.54%, respectively, from last year [1]. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), has a remarkable history of outdoing, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 24.78% lower. Albemarle is currently a Zacks Rank #4 (Sell) [1].

The Chemical - Diversified industry, part of the Basic Materials sector, is currently bearing a Zacks Industry Rank of 228, placing it in the bottom 8% of all 250+ industries [1]. The Zacks Industry Rank assesses the strength of separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups.

Realta Investment Advisors, an institutional investor, lessened its stake in Albemarle by 19.2% in the 1st quarter, according to the company's most recent 13F filing with the SEC. SteelPeak Wealth LLC, Alps Advisors Inc., Envestnet Asset Management Inc., Concurrent Investment Advisors LLC, and Pacific Heights Asset Management LLC all made changes to their positions in Albemarle during the same period [3].

Several equities analysts have commented on the company. Scotiabank, Wall Street Zen, Mizuho, UBS Group, and Piper Sandler have set price targets ranging from $57.00 to $76.00 and issued ratings from "sell" to "underweight" [3]. The stock has an average rating of "Hold" and an average target price of $91.19 [3].

References:
[1] https://finviz.com/news/108318/albemarle-alb-rises-as-market-takes-a-dip-key-facts
[2] https://www.barchart.com/story/news/33384695/what-you-need-to-know-ahead-of-albemarle-s-earnings-release
[3] https://www.marketbeat.com/instant-alerts/filing-albemarle-corporation-nysealb-shares-sold-by-realta-investment-advisors-2025-07-12/